Introduction
Good Manufacturing Practices (GMP) requirements are recognized as the backbone of safety and quality in the pharmaceutical industry. Although the common goal of all GMP systems is to ensure the production of safe, effective, and consistent quality medicines, there are differences in implementation between the main regulatory bodies, such as the European Medicines Agency (EMA), the US Food and Drug Administration (FDA), and the Pharmaceutical Inspection Cooperative Initiative (PIC/S). This article provides a comparative review of these requirements, focusing on manufacturers of pharmaceutical active ingredients (APIs) and finished drugs.
1. Legal framework and supervisory institutions
- Europe (EMA): GMP requirements in the European Union are enforced under the EU GMP Regulation and by the European Medicines Agency and national bodies (such as the MHRA in the UK or the ANSM in France).
- USA (FDA): In the United States, requirements are defined under federal law (21 CFR Parts 210 and 211) and are inspected and enforced by the FDA.
- PIC/S: A group of over 50 regulatory bodies that aims to harmonize GMP inspection requirements and methods internationally. The PIC/S regulations are largely similar to EU requirements, but have a stronger international dimension.
2. Differences in the structure of GMP documentation
- EU: High focus on Quality Management System (QMS), preparation of formal documentation such as Quality Manual, SOPs and Risk Assessment
- FDA: Special Emphasis on Data Integrity, Record Keeping, and Traceability
- PIC/S: A combination of both approaches; with special emphasis on Continuous Improvement and Harmonization
3. Human Resources Requirements
- EU: Precise definition of roles such as Qualified Person (QP)
- FDA: Continuous staff training and direct responsibility of senior management
- PIC/S: Requirement for risk-based training and its careful documentation
4. Quality control and process validation
- EU: Focus on Comprehensive Validation (Prospective, Concurrent, Retrospective)
- FDA: Life Cycle Approach for Processes (Process Design, Qualification, Continued Verification)
- PIC/S: Acceptance of both models and emphasis on complete documentation and verifiability of results
5. Sustainability studies and record keeping
- EU: Full compliance with ICH Q1 guidelines and data retention for at least 1 year after product expiration
- FDA: Data retention for at least 3 years after the last batch is produced
- PIC/S: Consistent with ICH standards and adaptable to member country needs
6. Inspection and risk-based
- EU: Routine and risk-based inspections coordinated by member institutions
- FDA: Unannounced inspections and focus on high-risk manufacturers or consumer complaints
- PIC/S: Promoting joint inspections between countries and using tools such as CAPA and RCA
7. The Importance of Data Integrity
- FDA: A pioneer in enforcing strict data accuracy requirements
- EU: Similar standards with emphasis on electronic data transparency
- PIC/S: Providing complementary guidelines for maintaining data security in digital systems
8. GMP for APIs (ICH Q7)
- All of these organizations have adopted the ICH Q7 principles as a reference for the production of APIs.
- The differences lie mostly in how the inspection is conducted and reported.
9. Acceptable certificates and documents
- EU: GMP Certificate issued by an EMA member institution is also valid for other countries.
- FDA: Issuing a Warning Letter or 483 in case of violation instead of a positive certificate
- PIC/S: Issuing GMP Certificate with the ability to be recognized by other members
Conclusion
While the overall goal of all GMP systems is the same, manufacturers should pay close attention to the operational, structural, and documentation differences between these entities. Understanding and implementing the specific requirements of each region not only prevents delays in product approval, but also provides an opportunity to increase brand credibility and enter new markets.
